N/A N=59 Mobile Cognitive Behavior Therapy Targeting Anxiety Disorders
Anxiety Disorders and Symptoms
Primary: Change in Anxious Symptoms From Baseline to End of Treatment (Week 6) — 4.78; 6.93; 6.09 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 Correlation of Trust and Outcomes Following Physical Therapy for Chronic Low Back Pain
Trust · Chronic Low Back Pain · Physical Therapy
Primary: Change in Patient Care Assessment Survey — 3.3 score on a scale
Phase 4 N=71 Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients
Complication of Transplant
Primary: Compare AUC 0-12hr of Each Tacrolimus Formulation in Expressor and Non Expressor Transplant Recipients — 112.35; 92.37; 97.04; 84.16 ng*hr/ml
N/A N=1,034 The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal
Penicillin Allergy
Primary: Penicillin Allergy Label Removal — 45; 31 Participants
Phase 4 N=217 Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
COVID-19
Primary: Number of Participants With Treatment Emergent Amino Acid Substitutions Greater Than (>) 5 Percent (%) and >50% Allelic Frequency in the Sotrovimab Epitope at Day 7…
Phase 1 N=116 Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
Metastatic Colorectal Cancer
Primary: Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) — 16.7; 0.0; 0.0; 27.3 Percetange of Participants
Phase 3 N=47 Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
Heart Failure
Primary: Number of Participants All-cause Mortality, Measured at 1 Year. — 0; 0; 0; 1 Participants — p=1.000
N/A N=49 Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
Phase 1 N=12 Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) Following Single Dose of GSK3923868 — 1; 2; 1; 0 Participants
Phase 1 N=23 AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer
Primary: Part 1: Number of Participants Who Experienced Dose-limiting Toxicity (DLT) — 0; 1; 1 Participants
N/A N=9 Object Finder for a Retinal Prosthesis
Retinitis Pigmentosa
Primary: Performance (Completion Time) Locating a Cell Phone and a Person — 47; 11; 30; 23 time (s)
Phase 2 N=16 Topical Ruxolitinib in Chronic Hand Dermatitis
Chronic Hand Dermatitis
Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants
Phase 2 N=29 Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)
Pulmonary Arterial Hypertension
Primary: Area Under the Curve 0-24h (AUC0-24h) (ng.h/mL) - 50 mg — 155; 761; 1570; 172 ng.h/mL
Phase 4 N=70 "Comparison of Intra-articular of 0.2% Ropivacaine vs. 0.75% Ropivacaine in Postoperative of Knee Arthroscopy"
Knee Arthroscopy · Acute Pain
Primary: Number of Participants With Acute Pain (Visual Analogue Scale) — 10; 29 Participants
Phase 3 N=40 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
Dry Eye Syndrome
Primary: Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score — -6.8 score on a scale